Testing ICP-723 for advanced solid tumors you can’t remove
Part of Cancer clinical trials.
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (or a primary brain tumor) that can’t be fully removed by surgery or has spread
- You’re the right age: 18+ or (if 12–17) you may be in a separate teen group
- Your cancer has at least one measurable problem area doctors can track on scans
- Your overall health score must be within the allowed range (ECOG for adults; Karnofsky/Lansky for younger people)
- You have expected survival of more than 3 months and can attend study visits
- You can safely use birth control during the study and for 12 weeks after the last dose (if you could become pregnant or father a child)
- You can sign consent and agree to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an experimental drug called ICP-B794 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and begins to show signs of shrinking tumors.
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.